secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2022-03-29T23:59:59+00:00
Accession:  0001654954-22-003966
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech appoints Jennifer Chao to Board; grants 30,000-share option
-------------------------------------------------------------------------

- Jennifer Chao appointed to fill board vacancy, effective March 28, 2022; term expires at 2022 annual meeting.
- Chao granted option to purchase 30,000 common shares at $2.94/share, vesting monthly over 12 months.
- She will serve on the Nominating and Compensation Committees.
- Chao is Managing Partner of CoreStrategies Management and serves on boards of Endo International (ENDP) and Cardiol Therapeutics (CRDL).
- Over 25 years biotech/life sciences experience; former managing director at Deutsche Bank, RBC Capital Markets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000165495422003966/0001654954-22-003966-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000165495422003966/edsa_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-003966

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer